|
|
 |
|
Viewing report
|
|
|
|
Concepts in Genetic Medicine
John Wiley and Sons Ltd, Feb 2008, Pages: 377
Introduction.
Chapter 1: The Evolution of Human Gene Therapy. A Journey from Excessive Hype to Excessive Diffidence to Realty.(Theodore Friedmann).
Delivery Systems.
Chapter 2: Murine Leukemia Virus Based Vectors.(Kenneth Cornetta).
Chapter 3: Lentivirus Vectors (Gwendolyn K. Binder and Boro Dropulic).
Chapter 4: Adenoviral Vectors: History and Perspective (Douglas J. Jolly, Estuardo Aguilar-Cordova, and Laura K. Aguilar).
Chapter 5: Adeno-associated Virus Vectors (Barrie J. Carter).
Chapter 6: The Glass is Half Full: the Goal of Long-term delivery may be Approachable Using SV40-derived Vectors (David S. Strayer).
Chapter 7: Herpes Simplex Virus Vectors (Anna-Marie Anesti and Robert S. Coffin).
Chapter 8: Nonviral Gene Delivery Systems (Takeshi Suda and Dexi Liu).
Applications.
Chapter 9: Therapeutic Gene Transfer to Skeletal Muscle (Paul Gregorevic and Jeffrey S. Chamberlain).
Chapter 10: Gene Therapy for Cardiovascular Disease (Christina A. Pacak, Kerry O. Cresawn, and Barry J. Byrne).
Chapter 11: Intra-articular Vector Delivery for Inflammatory Disease (Haim Burstein).
Chapter 12: The Respiratory System as a Platform for Gene Delivery (Barrie J. Carter).
Chapter 13: The Brain as a Target for Gene Therapy (Pedro R. Lowenstein and Maria G. Castro).
Chapter 14: Immune Responses to Viral vectors Injected Systemically or into the CNS (Pedro R. Lowenstein and Maria G. Castro).
Chapter 15: Cancer vaccines (Rimas J. Orentas).
Chapter 16: Genetically Modified T cells for Human Gene Therapy (James L. Riley and Carl June).
Chapter 17: Lentiviral Vector Delivery of RNAi Triggers for the Treatment of HIV-1 Infection (Kevin V. Morris ands John J. Rossi).
Manufacture.
Chapter 18: The Manufacture of Genetic Viral Vector Products (Douglas J. Jolly and Estuardo Aguilar-Cordova).
Chapter 19: The Manufacture of Adeno-associated Viral Vectors (Richard Peluso).
Chapter 20: Lentivirus Vector Manufacturing (Gwendolyn K.Binder and Boro Bropulic).
Safety and Regulatory.
Chapter 21: Assays for the Release of Viral Vector Gene Therapy Products for Clinical Trials (Flavia Borellini).
Chapter 22: Safety of Retroviral Vectors: Regulatory and Technical Considerations (Kenneth Cornetta and Carolyn Wilson).
Chapter 23: Assays for the Quality Control of Lentiviral Vectors (James Miskin, Susan M. Kingsman, and Kyriacos A. Mitrophanous).
Chapter 24: Assays for Non-viral vectors (Ralph W. Paul).
Chapter 25: Assays for the Release of Cellular Gene Therapy Products (Philip J. Cross and Bruce L. Levine).
Chapter 26: Toxicology for Gene Therapy Products: Concepts and Challenges (Russette M. Lyons).
Chapter 27: Regulatory Aspects of Gene Therapy Medicinal Products in the European Union (Matthias Schweizer, Christian Buchholz and Klaus Cichutek).
Finance and Reimbursment.
Chapter 28: Venture Capital and Biotechnology Startups (Douglas D. Lind).
Chapter 29: The role of Investment Banking in the Growth of Biotechnology Companies (Douglas J. Swirsky).
Chapter 30: Managing Reimbursment for Gene Therapy Products (Martin Gold).
Customers who bought this item also bought
Gene Therapy - Technologies, Markets and Companies
Immunology of Gene Therapy
Gene Therapy - Global Strategic Business Report
Viral Therapy of Cancer
U.S. Gene Therapy Markets
Gene Therapy: Current Status and Prospects
Gene Therapy-Industry Impact
Gene Therapy - Worldwide Market Challenges & Opportunities
Gene Therapy - Worldwide Market Challenges & Opportunities
Gene Therapy Companies
Gene Transfer: Delivery and Expression of DNA and RNA, A Laboratory Manual
Gene Therapy: It’s Finally Starting to Work! Immediate Opportunities and Future Implications
|
|
|
|
